Dr. Jonathan M. Green Selected as CEO of the NIH Clinical Center

Why It Matters

Green’s expertise in research ethics and clinical care will shape the Center’s ability to accelerate groundbreaking trials while safeguarding participants, reinforcing the U.S. leadership in translational medicine.

Key Takeaways

• Dr. Green to lead NIH Clinical Center starting May 17, 2026.
• Oversees $700 million annual budget and 200‑bed research hospital.
• Expansion adds 570,000 sq ft, slated for completion 2029.
• Previously centralized NIH’s 12 IRBs into a single entity.
• Last year: 3,000 inpatient admissions, 72,000 outpatient visits.

Pulse Analysis

The National Institutes of Health’s Clinical Center, the world’s largest hospital devoted exclusively to clinical research, has appointed Dr. Jonathan M. Green as its chief executive officer. Green will assume the role on May 17, 2026, taking charge of a 200‑bed, 870,000‑square‑foot facility that handled more than 3,000 inpatient admissions and roughly 72,000 outpatient visits in the most recent fiscal year. With an annual operating budget near $700 million, the Center serves as a critical bridge between laboratory discoveries and patient‑focused therapies, making the leadership change a focal point for the nation’s translational research agenda.

Green’s résumé blends clinical expertise with a proven track record in research governance. As director of NIH’s Office of Human Subjects Research Protections, he consolidated twelve institute‑specific Institutional Review Boards into a single, centralized IRB, streamlining ethical review for intramural studies. His prior tenure at Washington University School of Medicine, where he led IRB operations and investigated T‑cell activation, equips him to balance rigorous patient safety standards with the agility needed for innovative trials. Stakeholders anticipate that his dual focus on ethics and science will reinforce public trust while accelerating therapeutic development.

The Clinical Center is currently undergoing a massive expansion that will add over 570,000 square feet of modernized space, slated for completion in 2029. The new facilities are designed to accommodate advanced imaging, precision‑medicine suites, and flexible trial units, positioning the Center to host larger, more complex studies and to attract industry partnerships. Coupled with Green’s leadership, the expanded campus is expected to boost enrollment capacity, shorten time‑to‑therapy, and reinforce the United States’ competitive edge in biomedical innovation. The investment underscores federal commitment to sustaining a pipeline of breakthrough treatments.